Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
There is no current evidence to support or refute the routine use of aerosolized prostacyclin for patients with acute lung injury (ALI) and acute respiratory distress (ARDS).
ALI and ARDS are critical conditions that are associated with high mortality and morbidity. Aerosolised prostacyclin has been used to improve oxygenation despite the limited evidence available so far. This review assesses the benefits and harms of aerosolised prostacyclin in critically ill patients with acute lung injury and acute respiratory distress syndrome.
We’ve already reached tens of thousands of people with plain language summaries of systematic reviews. If you’d like to help us to continue our work, please consider a donation.
Donate with PayPal
You can also donate through the Charities Aid Foundation (CAF) here. If you are based in the USA and want to make a tax-deductable donation, please donate to Evidence Aid via the British Schools and Universities Foundation.